Skip to content
中文EN

Clinical readouts

Phase III and pivotal trial results — positive and negative, treated alike.

391 picksRelatedSafety signalsRegulatoryOncology

Latest picks

21–39 of 391
Oct 16Fri
  1. WeChat70

    GC101 Phase III Trial Hits Primary Endpoint With Head-to-Head Superiority Design

    GC101, an AAV gene therapy from Jinlan Genes, met the primary endpoint in a Phase III confirmatory trial. The trial used a randomized, head-to-head, active-controlled superiority design against an existing treatment. The source calls it a milestone for domestic AAV gene therapy in rare disease but discloses no efficacy data or indication name.

    Why it matters: The trial is explicitly head-to-head randomized and superiority-designed, letting readers weigh the positive result against existing treatments.

  2. WeChat61

    Mirikizumab one-year data show steroid-free disease control in ulcerative colitis and Crohn's disease

    One year of mirikizumab (Omvoh) produced steroid-free outcomes in two Lilly trials. In LUCENT-2, 27.7% of ulcerative colitis patients achieved comprehensive steroid-free disease control, and in VIVID-1, 20.4% of Crohn's disease patients achieved steroid-free deep remission. The results extend mirikizumab's reported efficacy profile to composite one-year endpoints in both conditions.

    Why it matters: New one-year composite endpoint data for mirikizumab in both ulcerative colitis and Crohn's disease.

  3. Nature48

    EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial

    A phase 1 trial of D2C7-ATC, an antibody-toxin conjugate targeting EGFR and EGFRvIII, in patients with recurrent malignant glioma showed encouraging safety and efficacy signals. Translational analyses of patient samples indicated intratumoral and systemic immune activation. The results support the conjugate as a candidate strategy for recurrent malignant glioma.

    Why it matters: Phase 1 data on an EGFR/EGFRvIII-targeted antibody-toxin conjugate in recurrent malignant glioma with immune activation evidence.

  4. Medical Xpress64

    Prescribing antidepressants based on patients' genetic makeup does not improve the effectiveness of treatment

    The double-blind randomized controlled PRESIDE trial enrolled 552 patients aged 18-65 with moderate-to-severe depression across 19 general practices in Australia, comparing prescribing recommendations based on CYP2C19 and CYP2D6 genotypes with standard care following Australian Therapeutic Guidelines.

    Why it matters: The PRESIDE trial found pharmacogenomics-guided antidepressant prescribing in primary care no better than guideline-based care, suggesting precision prescribing does not improve outcomes for all depression patients.

  5. 顶刊论文（社媒热度）89

    Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.

    A single intravenous infusion of the in vivo CRISPR gene-editing therapy lonvoguran ziclumeran cut monthly hereditary angioedema attack rates by 87% relative to placebo in a phase 3 trial of 80 patients with C1 inhibitor deficiency. From weeks 5 through 28, the mean monthly attack rate was 0.26 with lonvo-z versus 2.10 with placebo (P<0.001), with no serious or grade 3 or higher adverse events in the treatment group. The results support a one-time infusion replacing ongoing preventive therapy for this disease.

    Why it matters: Phase 3 evidence that one-time in vivo CRISPR editing nearly eliminates attacks in hereditary angioedema.

  6. 顶刊论文（社媒热度）53

    Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

    A personalized neoantigen long-peptide vaccine (NeoVax with poly-ICLC), combined with delayed anti-PD-1 antibody, was feasible and safe in ten patients with platinum-sensitive high-grade epithelial ovarian cancer after platinum doublet chemotherapy. Nine of twelve evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%), over 70% of targets remained detectable in cell-free DNA despite a median 6.5-month biopsy-to-vaccine interval, and biomarker analysis suggested biologic activity in six of ten patients. Resistant tumor clones showed defects in antigen presentation, consistent with vaccine-driven immune pressure.

    Why it matters: Shows personalized neoantigen vaccination is feasible and immunologically active in ovarian cancer, a tumor type with few such data.

  7. WeChat70

    Cerevance Parkinson's Drug Solengepras Hits Primary Endpoint in Phase III

    Cerevance announced that the Phase III ARISE trial of solengepras (CVN424) met its primary endpoint, with the 150 mg group showing a reduction of 0.61 hours in mean daily OFF time versus placebo at week 12. The drug is a selective inverse agonist targeting GPR6 through a non-dopaminergic mechanism, and the company plans to discuss the path to a marketing application with the FDA.

    Why it matters: The 0.61-hour OFF-time reduction and motor function improvement let readers compare effect size with existing Parkinson's adjunctive therapies.

Oct 15Thu
  1. WeChat72

    Jinlan Gene's GC101 Gene Therapy Meets Primary Endpoint in Confirmative Spinal Muscular Atrophy Trial

    GC101, an adeno-associated virus injection developed by Jinlan Gene, met its primary endpoint and key secondary endpoints in a confirmatory phase III trial for spinal muscular atrophy (5qSMA). The trial is the first internationally to use a superiority design in a head-to-head, randomized, controlled study of an SMA gene therapy against an existing treatment. The result positions GC101 to become the first domestically approved SMA therapy in China.

    Why it matters: First superiority-design head-to-head gene therapy trial in SMA met its primary endpoint, moving GC101 toward approval.

  2. 顶刊论文（社媒热度）76

    Long-Acting HIV Therapy in African Adults with Adherence Challenges.

    Long-acting injectable cabotegravir plus rilpivirine every 8 weeks maintained viral suppression in African adults with HIV and adherence challenges, matching daily oral dolutegravir-based therapy. At week 48, 91.0% of the long-acting group (244 of 268) had a viral load below 50 copies per milliliter versus 89.2% of the oral group (240 of 269), meeting noninferiority. Confirmed virologic failure occurred in 5 participants (1.9%) on long-acting therapy and none on oral therapy.

    Why it matters: It tests long-acting injectable HIV therapy in the population most affected by adherence failure: African adults with suboptimal adherence.

  3. 顶刊论文（社媒热度）77

    Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.

    Once-daily oral icotrokinra, a peptide that blocks the interleukin-23 receptor, beat placebo for clinical response at week 12 in adults with moderately to severely active ulcerative colitis: 63% at 400 mg, 58% at 200 mg and 55% at 100 mg versus 27% on placebo (P<0.001 for all). The 400-mg group also showed more clinical remission (30% vs. 11%), symptomatic remission (46% vs. 19%) and endoscopic improvement (37% vs. 14%). It offers an oral alternative to injected interleukin-23-targeted antibodies.

    Why it matters: An oral interleukin-23 receptor blocker matched injected antibodies' mechanism with positive phase 2 results.

  4. BioSpace61

    Vanda freezes Novartis-originated social anxiety program after late-stage disappointment

    VQW-765, an alpha 7 nicotinic acetylcholine receptor partial agonist licensed from Novartis, failed its Phase 3 trial in social anxiety disorder. In study VP-VQW-765-3201, 546 adults with elevated baseline anxiety received VQW-765 or placebo before a standardized social stress test, and the drug did not significantly reduce distress versus placebo in female participants, the primary outcome. Vanda has put the program on hold pending further analysis.

    Why it matters: A Phase 3 failure overturns promising sex-stratified Phase 2 findings and halts a licensed social anxiety program.

  5. WeChat81

    VERIFY Phase 3: Rusfertide Improves Hematocrit Control and Cuts Phlebotomy Need in Polycythemia Vera

    Rusfertide improved hematocrit control in polycythemia vera patients who were phlebotomy-dependent with poorly controlled hematocrit. In the VERIFY phase 3 study, 77% of rusfertide patients needed no phlebotomy between weeks 20 and 32 versus 33% of controls, and 63% maintained hematocrit below 45% versus 14%, with mean phlebotomies of 0.5 versus 1.8 (all P<.0001). It offers an alternative to repeated phlebotomy in these patients.

    Why it matters: Phase 3 data show rusfertide reduced phlebotomy dependence in polycythemia vera across multiple endpoints.

  7. New England Journal of Medicine54

    Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL

    Italy's GIMEMA collaborative group published a randomized controlled trial in NEJM involving adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), comparing ponatinib plus blinatumomab against imatinib plus chemotherapy. The feed only provides the journal citation (Volume 395, Issue 15, 1483-1494); no full abstract was given.

    Why it matters: Traffic: 6401 views; 2 sources reported the same event.

  8. 顶刊论文（社媒热度）71

    Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury.

    Starting renal-replacement therapy with intermittent hemodialysis rather than continuous renal-replacement therapy was not noninferior in critically ill adults with acute kidney injury. The trial stopped early after 554 patients were randomized because of higher mortality with intermittent hemodialysis: day-90 death occurred in 63.1% versus 53.5%, and major adverse kidney events in 78.1% versus 71.6%. Clinicians choosing an initial modality now have mortality evidence favoring continuous therapy.

    Why it matters: It gives clinicians comparative mortality evidence for choosing the initial renal-replacement modality in acute kidney injury.

  9. JAMA69

    Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial.

    A hospital-level strategy of starting fixed-dose vasopressin at 0.1 µg/kg/min norepinephrine-equivalent did not reduce 28-day mortality compared with starting at 0.4 µg/kg/min in septic shock (31.8% vs 33.0%; adjusted OR 0.98, 95% CI 0.87-1.06). The trial randomized 13 hospitals in a cluster-crossover design and included 3959 patients; kidney replacement therapy-free days were also unchanged. Clinicians can defer second-line vasopressin without a mortality penalty.

    Why it matters: Large pragmatic trial showing the timing of adding vasopressin in septic shock does not change mortality.

  10. JAMA67

    Isoflurane-Based Inhaled Sedation in Mechanically Ventilated Adults With Acute Hypoxemic Respiratory Failure: The SAVE-ICU Randomized Clinical Trial.

    An isoflurane-based inhaled sedation strategy did not reduce hospital mortality in mechanically ventilated adults with acute hypoxemic respiratory failure compared with usual intravenous sedation. In the SAVE-ICU trial of 780 adults across 14 Canadian ICUs, 42.5% died in the inhaled sedation group versus 43.8% with intravenous sedation (risk ratio, 0.98; P = .85). Isoflurane patients received more adjunctive therapies for hypoxemia and had fewer delirium- and coma-free days.

    Why it matters: Large randomized trial shows no mortality benefit and some signals of harm for isoflurane sedation in ventilated AHRF patients.

  11. 中文产业新闻82

    DESTINY-Breast11 RCB Analysis Shows T-DXd-THP Cuts Residual Burden in High-Risk HER2-Positive Early Breast Cancer

    In the phase 3 DESTINY-Breast11 trial in high-risk HER2-positive early breast cancer, neoadjuvant T-DXd followed by paclitaxel, trastuzumab and pertuzumab (T-DXd-THP) achieved a pCR rate of 67.3% versus 56.3% with dose-dense doxorubicin-cyclophosphamide followed by THP, and a prespecified RCB analysis presented at ESMO BC 2026 showed an RCB-0+I rate of 81.3% versus 69.1%. The RCB index distribution shifted toward lower residual burden (Q3/Q4 boundary 1.01 vs 1.38, P=0.0059), and among patients not reaching pCR the median RCB was 1.5 versus 1.7. The findings add pathologic-response detail beyond the binary pCR endpoint to guide postoperative adjuvant decisions in an anthracycline-free regimen.

    Why it matters: Phase 3 RCB data quantify how T-DXd-THP reduces residual disease beyond pCR in high-risk HER2-positive early breast cancer.

  12. WeChat65

    BioNTech BNT113 Plus Keytruda Misses PFS Endpoint in HPV16-Positive Head and Neck Cancer Trial

    BioNTech's BNT113 combined with pembrolizumab (Keytruda) failed to reach progression-free survival, a co-primary endpoint, in the phase II/III AHEAD-MERIT trial (NCT04534205) in HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma. The independent data monitoring committee recommended continuing the study pending final analysis of the other co-primary endpoint, overall survival. The miss comes nine months after the vaccine drew high industry expectations.

    Why it matters: Phase II/III miss on PFS for a leading therapeutic HPV cancer vaccine combination.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org